Kala Pharmaceuticals (NASDAQ:KALA) issued its earnings results on Thursday. The company reported ($0.68) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.01), Fidelity Earnings reports. The firm had revenue of $1.45 million during the quarter, compared to the consensus estimate of $3.56 million.
KALA stock traded up $0.40 during mid-day trading on Friday, reaching $4.11. 374,000 shares of the company traded hands, compared to its average volume of 249,192. The company has a quick ratio of 7.04, a current ratio of 7.50 and a debt-to-equity ratio of 1.16. The stock has a market cap of $126.17 million, a price-to-earnings ratio of -1.66 and a beta of 2.13. The firm’s 50 day moving average price is $3.84 and its 200 day moving average price is $5.11. Kala Pharmaceuticals has a fifty-two week low of $3.24 and a fifty-two week high of $9.25.
Several analysts have recently commented on KALA shares. HC Wainwright reduced their target price on Kala Pharmaceuticals from $15.00 to $12.00 and set a “buy” rating for the company in a research note on Wednesday, August 7th. Wedbush restated an “outperform” rating and issued a $51.00 target price on shares of Kala Pharmaceuticals in a research note on Wednesday, August 7th. Oppenheimer set a $9.00 target price on Kala Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 7th. Zacks Investment Research upgraded Kala Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 target price for the company in a research note on Wednesday. Finally, ValuEngine upgraded Kala Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Kala Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $17.54.
Kala Pharmaceuticals Company Profile
Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.
Featured Article: Stochastic Momentum Index (SMI)
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.